한글목차

세계 항체 약물 접합체(ADC) 시장 규모는 2035년에 걸쳐 CAGR 14.9%로 성장할 것으로 예측됩니다.

항체 약물 접합체(ADC)의 상승

항체 약물 접합체(ADC) 는 표적 치료의 정확성과 세포 독성 약물의 효능을 융합하여 암 치료에 혁명을 가져옵니다. 세포에 직접 전달하고 표적 외 작용과 전신 독성을 완화합니다.

또한 2023년 현재 90개가 넘는 ADC 후보가 임상시험 중이며 견고하고 유망한 파이프라인의 존재를 보여주고 있습니다. 적용 확대로가는 길을 열고 있습니다. Sankyo 등 기업이 세계의 이정표를 달성하는 등 신흥기업과 기존 제약기업이 협력하여 이러한 한계를 더욱 넓히려 하고 있습니다.

항체 약물 접합체(ADC)의 등장은 정밀암 치료의 진화에 있어 중요한 이정표가 됩니다. 한편 부작용을 줄이고 있습니다. 이 정확도는 바이오 마커 식별과 같은 분자진단학의 진보에 의해 증폭되어 개별 환자의 요구에 맞는 치료를 가능하게하고 있습니다.

이 보고서는 세계 항체 약물 접합체(ADC) 시장을 조사했으며, 시장 개요, 시장 성장에 미치는 영향요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 다양한 분류 및 지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
• 영향 분석
  • 시장 견인 요인
  • 시장 성장 억제요인
  • 시장 기회
• SWOT 분석
• 규제 프레임워크
• Porter's Five Forces 분석
• PEST 분석
• 항체 약물 접합체(ADC)의 현재 연구 개발 및 임상 상황
• ADC의 의료 업무에 관한 주요 고려 사항
• 상업상의 과제
• 제약 업계는 ADC 발매의 제2파를 기대하고 있다
• 승인된 ADC

제4장 항체 약물 접합체(ADC) 시장 분석 : 페이로드 유형별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추이와 예측
• MMAE
• DM4
• 캄프토테신
• DM1
• MMAF
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제5장 항체 약물 접합체(ADC) 시장 분석 : 링커 유형별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추이와 예측
• 절단 가능 링커
• 절단 불가능 링커
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제6장 항체 약물 접합체(ADC) 시장 분석 : 표적 항원별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추이와 예측
• CD30
• HER2
• CD22
• CD33
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제7장 항체 약물 접합체(ADC) 시장 분석 : 용도별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추이와 예측
• 혈액암
• 유방암
• 난소암
• 폐암
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제8장 항체 약물 접합체(ADC) 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이와 예측

제9장 북미의 항체 약물 접합체(ADC) 시장 분석

제10장 유럽 항체 약물 접합체(ADC) 시장 분석

제11장 아시아태평양의 항체 약물 접합체(ADC) 시장 분석

제12장 라틴아메리카 항체 약물 접합체(ADC) 시장 분석

제13장 중동 및 아프리카 항체 약물 접합체(ADC) 시장 분석

제14장 기업 프로파일

• 경쟁 환경
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• AstraZeneca
• Gilead Sciences, Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Company, Limited
• GSK plc
• ADC Therapeutics SA
• Synaffix BV(now a part of Lonza)
• Byondis
• AbbVie Inc.
• RemeGen
• Oxford BioTherapeutics
• Mersana Therapeutics
• WuXi AppTec
• Genmab A/S
• Regeneron Pharmaceuticals Inc.

제15장 총론·제안

• Visiongain에 의한 총론
• 참가 기업에 대한 제안

영문목차

The global Antibody Drug Conjugates market is projected to grow at a CAGR of 14.9% by 2035.

The Antibody Drug Conjugates Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rise of Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) are revolutionizing cancer therapy by merging the precision of targeted treatment with the potency of cytotoxic agents. These innovative therapies deliver powerful payloads, such as DNA-damaging agents or microtubule inhibitors, directly to cancer cells, reducing off-target effects and systemic toxicity. This advancement has allowed ADCs to expand their efficacy from treating haematological cancers to solid tumours, addressing complex malignancies like ovarian and lung cancers.

Additionally, over 90 ADC candidates in clinical trials, as of 2023, signal a robust and promising pipeline. Breakthroughs such as bispecific ADCs and combination therapies are paving the way for higher success rates and expanded applications. Startups and established pharmaceutical players are collaborating to push these boundaries further, with companies like AstraZeneca and Daiichi Sankyo achieving global milestones.

For instance, on 19th October 2023, Daiichi Sankyo and Merck entered a global agreement to jointly develop and potentially commercialize three of Daiichi Sankyo's DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). This collaboration will cover worldwide development and commercialization, excluding Japan, where Daiichi Sankyo will retain exclusive rights. Additionally, Daiichi Sankyo will handle all manufacturing and supply operations. While production challenges and cost concerns remain, the future of ADCs appears bright, driven by continuous innovation and strategic investments.

Antibody-Drug Conjugates: Pioneering the Future of Precision Cancer Therapy

The advent of Antibody-Drug Conjugates (ADCs) marks a significant milestone in the evolution of precision cancer treatment. By targeting specific cancer antigens and delivering payloads with pinpoint accuracy, ADCs are reducing side effects while enhancing therapeutic outcomes. This precision has been amplified by advancements in molecular diagnostics, such as biomarker identification, enabling treatments to be tailored to individual patient needs.

However, the journey is not without hurdle, the ADC production demands specialized technologies and facilities, driving up costs and complicating reimbursement structures. For instance, disparities in coverage policies, even in developed regions like the UK, hinder patient access to these life-saving therapies. Yet, emerging economies like China and India show potential for growth as healthcare infrastructures evolve. Industry leaders, including Pfizer, F. Hoffmann-La Roche, Astellas Pharma Inc., GSK, and AstraZeneca among others are making strides to lower production costs and increase access. By fostering global collaborations and embracing innovation, ADCs are set to define the future of cancer therapy.

What Questions Should You Ask before Buying a Market Research Report?

• How is the antibody drug conjugates market evolving?
• What is driving and restraining the antibody drug conjugates market?
• How will each antibody drug conjugates submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
• How will the market shares for each antibody drug conjugates submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading antibody drug conjugates markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
• Who are the leading players and what are their prospects over the forecast period?
• What are the antibody drug conjugates projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2035? What are the implications of
• antibody drug conjugates projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the antibody drug conjugates market?
• Where is the antibody drug conjugates market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the antibody drug conjugates market today, and over the next 10 years:

• Our 342-page report provides 126 tables, 185 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
• Forecasts to 2035 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

• Payload Type
• MMAE
• DM4
• Camptothecin
• DM1
• MMAF
• Other Payload Type
• Linker Type
• Cleavable Linkers
• Non-Cleavable Linkers
• Target Antigen
• CD30
• HER2
• CD22
• CD33
• Other Target Antigens
• Applications
• Blood Cancer
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Other Applications

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• South-East Asia
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America
• MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles for some of the leading companies in the Antibody Drug Conjugates Market, 2025 to 2035, with a focus on this segment of these companies' operations.

• Leading companies and the potential for market growth
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• AstraZeneca
• Gilead Sciences, Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Company, Limited
• GSK plc
• ADC Therapeutics SA
• Synaffix BV
• Byondis
• AbbVie Inc.
• RemeGen
• Oxford BioTherapeutics
• Mersana Therapeutics
• WuXi AppTec
• Genmab A/S
• Regeneron Pharmaceuticals Inc.

Overall world revenue for Antibody Drug Conjugates Market, 2025 to 2035 in terms of value the market will surpass US$16.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

• How will the Antibody Drug Conjugates Market, 2025 to 2035 report help you?
• In summary, our 340+ page report provides you with the following knowledge:
• Revenue forecasts to 2035 for Antibody Drug Conjugates Market 2025 to 2035, with forecasts for Payload Type, Linker Type, Target Antigen, and Applications, each forecast at a global and regional level discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 21 key national markets See forecasts for the Antibody Drug Conjugates Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market including company profiles for 18 of the major companies involved in the Antibody Drug Conjugates Market, 2025 to 2035.
• Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
• Information found nowhere else
• With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Antibody Drug Conjugates Market 2025 to 2035, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Antibody Drug Conjugates Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report Include:
• 1.6 Who is This Report For?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
    • 3.3.1.1 Growing Burden of Cancer
    • 3.3.1.2 Increasing Breast Cancer Cases Driving Demand for Antibody-Drug Conjugates
    • 3.3.1.3 Presence of Strong Emerging Pipeline Drugs
    • 3.3.1.4 Increasing R&D Activities for the Development of Novel Therapeutics
  • 3.3.2 Market Restraining Factors
    • 3.3.2.1 Complexities in Manufacturing
    • 3.3.2.2 Co-ordination Between Various Biopharmaceutical and CDMOs
    • 3.3.2.3 Antibody and Linker-Related Cytotoxin and Formulation Challenges
    • 3.3.2.4 Adverse Effects of Antibody-Drug Conjugates
  • 3.3.3 Market Opportunities
    • 3.3.3.1 Adoption of Combination Therapies
    • 3.3.3.2 Advancements in Antibody-Drug Conjugates (ADCs)
    • 3.3.3.3 Expanding Industry Investments and Collaborations in ADC Development
• 3.4 SWOT Analysis
• 3.5 Regulatory Framework
• 3.6 Porter's Five Forces Analysis
  • 3.6.1 Bargaining Power of Suppliers
  • 3.6.2 Bargaining Power of Buyers
  • 3.6.3 Competitive Rivalry
  • 3.6.4 Threat of Substitutes
  • 3.6.5 Threat of New Entrants
• 3.7 PEST
  • 3.7.1 Political
  • 3.7.2 Economical
  • 3.7.3 Social
  • 3.7.4 Technological
• 3.8 Current R&D and Clinical Status of Antibody Drug Conjugates
  • 3.8.1 Antibody Drug Considerations
  • 3.8.2 Drug to Antibody Ration (DAR)
  • 3.8.3 Bystander Effect and Linker Design
  • 3.8.4 Future Clinical Differentiation
• 3.9 Key Medical Affairs Considerations for ADCs
  • 3.9.1 Precision in Indication and Timing
  • 3.9.2 Combination Partners and Customisation
  • 3.9.3 Balancing Dose and Toxicity
  • 3.9.4 Patient-Centred Decision Making
• 3.10 Commercial Challenges
  • 3.10.1 Physician Variability and Market Variability
  • 3.10.2 Reposition Value Narratives
  • 3.10.3 Reimbursement and Cost Considerations
• 3.11 Pharma is Expecting a Second Wave of ADC Launches
• 3.12 Approved ADCs

4 Antibody Drug Conjugates Market Analysis by Payload Type

• 4.1 Key Findings
• 4.2 Payload Type Segment: Market Attractiveness Index
• 4.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
• 4.4 MMAE
  • 4.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.4.2 Market Share by Region, 2025 & 2035 (%)
• 4.5 DM4
  • 4.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.5.2 Market Share by Region, 2025 & 2035 (%)
• 4.6 Camptothecin
  • 4.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.6.2 Market Share by Region, 2025 & 2035 (%)
• 4.7 DM1
  • 4.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.7.2 Market Share by Region, 2025 & 2035 (%)
• 4.8 MMAF
  • 4.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.8.2 Market Share by Region, 2025 & 2035 (%)
• 4.9 Other Payload Type
  • 4.9.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.9.2 Market Share by Region, 2025 & 2035 (%)

5 Antibody Drug Conjugates Market Analysis by Linker Type

• 5.1 Key Findings
• 5.2 Linker Type Segment: Market Attractiveness Index
• 5.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
• 5.4 Cleavable Linkers
  • 5.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 5.4.2 Market Share by Region, 2025 & 2035 (%)
• 5.5 Non-Cleavable Linkers
  • 5.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 5.5.2 Market Share by Region, 2025 & 2035 (%)

6 Antibody Drug Conjugates Market Analysis by Target Antigen

• 6.1 Key Findings
• 6.2 Target Antigen Segment: Market Attractiveness Index
• 6.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
• 6.4 CD30
  • 6.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.4.2 Market Share by Region, 2025 & 2035 (%)
• 6.5 HER2
  • 6.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.5.2 Market Share by Region, 2025 & 2035 (%)
• 6.6 CD22
  • 6.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.6.2 Market Share by Region, 2025 & 2035 (%)
• 6.7 CD33
  • 6.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.7.2 Market Share by Region, 2025 & 2035 (%)
• 6.8 Other Target Antigens
  • 6.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.8.2 Market Share by Region, 2025 & 2035 (%)

7 Antibody Drug Conjugates Market Analysis by Applications

• 7.1 Key Findings
• 7.2 Applications Segment: Market Attractiveness Index
• 7.3 Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
• 7.4 Blood Cancer
  • 7.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 7.4.2 Market Share by Region, 2025 & 2035 (%)
• 7.5 Breast Cancer
  • 7.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 7.5.2 Market Share by Region, 2025 & 2035 (%)
• 7.6 Ovarian Cancer
  • 7.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 7.6.2 Market Share by Region, 2025 & 2035 (%)
• 7.7 Lung Cancer
  • 7.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 7.7.2 Market Share by Region, 2025 & 2035 (%)
• 7.8 Other Applications
  • 7.8.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 7.8.2 Market Share by Region, 2025 & 2035 (%)

8 Antibody Drug Conjugates Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America Antibody Drug Conjugates Market Analysis

• 9.1 Key Findings
• 9.2 North America Antibody Drug Conjugates Market Attractiveness Index
• 9.3 North America Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 9.4 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
• 9.5 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
• 9.6 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Technology
• 9.7 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
• 9.8 North America Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
• 9.9 U.S. Antibody Drug Conjugates Market Analysis
• 9.10 Canada Antibody Drug Conjugates Market Analysis

10 Europe Antibody Drug Conjugates Market Analysis

• 10.1 Key Findings
• 10.2 Europe Antibody Drug Conjugates Market Attractiveness Index
• 10.3 Europe Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 10.4 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Country
• 10.5 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
• 10.6 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
• 10.7 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
• 10.8 Europe Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
• 10.9 Germany Antibody Drug Conjugates Market Analysis
• 10.10 UK Antibody Drug Conjugates Market Analysis
• 10.11 France Antibody Drug Conjugates Market Analysis
• 10.12 Italy Antibody Drug Conjugates Market Analysis
• 10.13 Spain Antibody Drug Conjugates Market Analysis
• 10.14 Russia Antibody Drug Conjugates Market Analysis
• 10.15 Rest of Europe Antibody Drug Conjugates Market Analysis

11 Asia Pacific Antibody Drug Conjugates Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Antibody Drug Conjugates Market Attractiveness Index
• 11.3 Asia Pacific Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 11.4 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Country
• 11.5 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
• 11.6 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
• 11.7 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
• 11.8 Asia Pacific Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
• 11.9 Japan Antibody Drug Conjugates Market Analysis
• 11.10 China Antibody Drug Conjugates Market Analysis
• 11.11 India Antibody Drug Conjugates Market Analysis
• 11.12 Australia Antibody Drug Conjugates Market Analysis
• 11.13 South Korea Antibody Drug Conjugates Market Analysis
• 11.14 South-East Asia Antibody Drug Conjugates Market Analysis
• 11.15 Rest of Asia Pacific Antibody Drug Conjugates Market Analysis

12 Latin America Antibody Drug Conjugates Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Antibody Drug Conjugates Market Attractiveness Index
• 12.3 Latin America Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 12.4 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Country
• 12.5 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
• 12.6 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
• 12.7 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
• 12.8 Latin America Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
• 12.9 Brazil Antibody Drug Conjugates Market Analysis
• 12.10 Mexico Antibody Drug Conjugates Market Analysis
• 12.11 Argentina Antibody Drug Conjugates Market Analysis
• 12.12 Colombia Antibody Drug Conjugates Market Analysis
• 12.13 Rest of Latin America Antibody Drug Conjugates Market Analysis

13 MEA Antibody Drug Conjugates Market Analysis

• 13.1 Key Findings
• 13.2 MEA Antibody Drug Conjugates Market Attractiveness Index
• 13.3 MEA Antibody Drug Conjugates Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 13.4 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Country
• 13.5 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Payload Type
• 13.6 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Linker Type
• 13.7 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Target Antigen
• 13.8 MEA Antibody Drug Conjugates Market Size Estimation and Forecast by Applications
• 13.9 GCC Antibody Drug Conjugates Market Analysis
• 13.10 South Africa Antibody Drug Conjugates Market Analysis
• 13.11 Rest of MEA Antibody Drug Conjugates Market Analysis

14 Company Profiles

• 14.1 Competitive Landscape
  • 14.1.1 Strategic Collaborations in the ADC Space to Redefine Cancer Treatment
  • 14.1.2 Pioneering Innovations Redefining Cancer Care and Broader Health Solutions
• 14.2 Takeda Pharmaceutical Company Limited
  • 14.2.1 Company Snapshot
  • 14.2.2 Company Overview
  • 14.2.3 Financial Analysis
    • 14.2.3.1 Net Revenue, 2018-2023
    • 14.2.3.2 R&D, 2018-2023
    • 14.2.3.3 Regional Market Shares, 2023
  • 14.2.4 Product Benchmarking
  • 14.2.5 Strategic Outlook
• 14.3 F. Hoffmann-La Roche Ltd.
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Net Revenue, 2018-2023
    • 14.3.3.2 R&D, 2018-2023
    • 14.3.3.3 Business Segment Market Shares, 2023
  • 14.3.4 Product Benchmarking
  • 14.3.5 Strategic Outlook
• 14.4 Pfizer Inc.
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Financial Analysis
    • 14.4.3.1 Net Revenue, 2018-2023
    • 14.4.3.2 R&D, 2018-2023
    • 14.4.3.3 Regional Market Shares, 2023
    • 14.4.3.4 Business Segment Market Shares, 2023
  • 14.4.4 Product Benchmarking
  • 14.4.5 Strategic Outlook
• 14.5 AstraZeneca
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Financial Analysis
    • 14.5.3.1 Net Revenue, 2018-2023
    • 14.5.3.2 R&D, 2018-2023
    • 14.5.3.3 Regional Market Shares, 2023
  • 14.5.4 Product Benchmarking
  • 14.5.5 Strategic Outlook
• 14.6 Gilead Sciences, Inc.
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Financial Analysis
    • 14.6.3.1 Net Revenue, 2018-2023
    • 14.6.3.2 R&D, 2018-2023
    • 14.6.3.3 Regional Market Shares, 2023
    • 14.6.3.4 Business Segment Market Shares, 2023
  • 14.6.4 Product Benchmarking
  • 14.6.5 Strategic Outlook
• 14.7 Astellas Pharma Inc.
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Financial Analysis
    • 14.7.3.1 Net Revenue, 2018-2023
    • 14.7.3.2 R&D, 2018-2023
    • 14.7.3.3 Regional Market Shares, 2023
  • 14.7.4 Product Benchmarking
  • 14.7.5 Strategic Outlook
• 14.8 Daiichi Sankyo Company, Limited
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Product Benchmarking
  • 14.8.4 Strategic Outlook
• 14.9 GSK plc
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Financial Analysis
    • 14.9.3.1 Net Revenue, 2018-2023
    • 14.9.3.2 R&D, 2018-2023
    • 14.9.3.3 Regional Market Shares, 2023
    • 14.9.3.4 Business Segment Market Shares, 2023
  • 14.9.4 Product Benchmarking
• 14.10 ADC Therapeutics SA
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Financial Analysis
    • 14.10.3.1 Net Revenue, 2018-2023
    • 14.10.3.2 R&D, 2018-2023
  • 14.10.4 Product Benchmarking
  • 14.10.5 Strategic Outlook
• 14.11 Synaffix BV (now a part of Lonza)
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Product Benchmarking
  • 14.11.4 Strategic Outlook
• 14.12 Byondis
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Product Benchmarking
• 14.13 AbbVie Inc.
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Financial Analysis
    • 14.13.3.1 Net Revenue, 2018-2023
    • 14.13.3.2 R&D, 2018-2023
    • 14.13.3.3 Regional Market Shares, 2023
    • 14.13.3.4 Business Segment Market Shares, 2023
  • 14.13.4 Product Benchmarking
  • 14.13.5 Strategic Outlook
• 14.14 RemeGen
  • 14.14.1 Company Snapshot
  • 14.14.2 Company Overview
  • 14.14.3 Product Benchmarking
  • 14.14.4 Strategic Outlook
• 14.15 Oxford BioTherapeutics
  • 14.15.1 Company Snapshot
  • 14.15.2 Company Overview
  • 14.15.3 Product Benchmarking
• 14.16 Mersana Therapeutics
  • 14.16.1 Company Snapshot
  • 14.16.2 Company Overview
  • 14.16.3 Product Benchmarking
• 14.17 WuXi AppTec
  • 14.17.1 Company Snapshot
  • 14.17.2 Company Overview
  • 14.17.3 Financial Analysis
    • 14.17.3.1 Net Revenue, 2018-2023
  • 14.17.4 Product Benchmarking
  • 14.17.5 Strategic Outlook
• 14.18 Genmab A/S
  • 14.18.1 Company Snapshot
  • 14.18.2 Company Overview
  • 14.18.3 Financial Analysis
    • 14.18.3.1 Net Revenue, 2018-2023
    • 14.18.3.2 R&D, 2018-2023
  • 14.18.4 Product Benchmarking
  • 14.18.5 Strategic Outlook
• 14.19 Regeneron Pharmaceuticals Inc.
  • 14.19.1 Company Snapshot
  • 14.19.2 Company Overview
  • 14.19.3 Financial Analysis
    • 14.19.3.1 Net Revenue, 2018-2023
    • 14.19.3.2 R&D, 2018-2023
    • 14.19.3.3 Regional Market Shares, 2023
    • 14.19.3.4 Business Segment Market Shares, 2023
  • 14.19.4 Product Benchmarking

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from Visiongain
• 15.2 Recommendations for Market Players